Abstract: The present disclosure provides synthesized peptides containing azetidine-2-carboxylic acid (Aze), methods for detecting antibodies to peptides containing Aze, and methods for diagnosing conditions associated with misincorporation of Aze into host proteins.

Abstract: The present disclosure provides synthesized peptides containing azetidine-2-carboxylic acid (Aze), methods for detecting antibodies to peptides containing Aze, and methods for diagnosing conditions associated with misincorporation of Aze into host proteins.

Abstract: Methods and systems for detecting azetidine-2-carboxylic acid (Aze) in food consumable by humans and animals are provided. Also provided are methods and systems for inactivating Aze in food and byproducts, as well as other methods for the diagnosis, prevention, and treatment of disorders associated with Aze.

Abstract: Methods and systems for detecting azetidine-2-carboxylic acid (Aze) in food consumable by humans and animals are provided. Also provided are methods and systems for inactivating Aze in food and byproducts, as well as other methods for the diagnosis, prevention, and treatment of disorders associated with Aze.

Abstract: Methods and systems for detecting azetidine-2-carboxylic acid (Aze) in food consumable by humans and animals are provided. Also provided are methods and systems for inactivating Aze in food and byproducts, as well as other methods for the diagnosis, prevention, and treatment of disorders associated with Aze.

Abstract: Methods and systems for detecting azetidine-2-carboxylic acid (Aze) in food consumable by humans and animals are provided. Also provided are methods and systems for inactivating Aze in food and byproducts, as well as other methods for the diagnosis, prevention, and treatment of disorders associated with Aze.

Abstract: A method treats a patient for adult-onset dementia of the Alzheimer's type by removing a portion of the patient's cerebrospinal fluid, preferably (although not necessarily) by transporting the fluid to another portion of the patient's body. An apparatus for removing cerebrospinal fluid includes (1) a conduit with a first opening and a second opening, the first opening of the conduit being disposed in fluid communication with a space within a patient's subarachnoid space, the second opening being disposed in fluid communication with another portion of the patient's body; and (2) a flow rate control device attached to the conduit.

Abstract: A method for treating a patient for adult-onset dementia of the Alzheimer's type by removing a portion of the patient's cerebrospinal fluid, preferably (although not necessarily) by transporting the fluid to another portion of the patient's body. The invention also provides an apparatus for removing cerebrospinal fluid including (1) a conduit with a first opening and a second opening, the first opening of the conduit being adapted to be disposed in fluid communication with a space within a patient's subarachnoid space, the second opening being adapted to be disposed in fluid communication with another portion of the patient's body; and (2) a flow rate control device attached to the conduit.

Abstract: A method for treating a patient for adult-onset dementia of the Alzheimer's type by removing a portion of the patient's cerebrospinal fluid, preferably (although not necessarily) by transporting the fluid to another portion of the patient's body. The invention also provides an apparatus for removing cerebrospinal fluid including (1) a conduit with a first opening and a second opening, the first opening of the conduit being adapted to be disposed in fluid communication with a space within a patient's subarachnoid space, the second opening being adapted to be disposed in fluid communication with another portion of the patient's body; and (2) a flow rate control device attached to the conduit.

Abstract: Choroid plexus failure in a subject is diagnosed and treated by measuring the level of one or more components of cerebrospinal fluid, comparing the level to a desired level, and adjusting the level toward the desired level. Treatment can occur using an implantable device.

Abstract: A method for treating a patient for adult-onset dementia of the Alzheimer's type by removing a portion of the patient's cerebrospinal fluid, preferably (although not necessarily) by transporting the fluid to another portion of the patient's body. The invention also provides an apparatus for removing cerebrospinal fluid including (1) a conduit with a first opening and a second opening, the first opening of the conduit being adapted to be disposed in fluid communication with a space within a patient's subarachnoid space, the second opening being adapted to be disposed in fluid communication with another portion of the patient's body; and (2) a flow rate control device attached to the conduit.

Abstract: Provided are compositions comprising nonprotein amino acids and modified amino acids, as well as methods for the use of nonprotein amino acids and modified amino acids in inhibiting the growth of infective agents. In one embodiment the compounds and compositions may be used for treating an infection in a human or animal. For example, infectious agents include resistant strains of Acinetobacter, Klebsiella, Serratia, Staphylococcus aureus and Streptococcus pneumoniae, vancomyocin-resistant enterococci and multi-drug resistant mycobacteria, and other emerging resistant organisms. The compounds and methods are useful for treating infections caused by organisms, including viral pathogens, fungi, yeast, helminths or protozoans. The nonprotein amino acids and modified amino acids may be administered by any route known in the air, such as parenterally, orally, by inhalation or topically, and optionally may be administered in a carrier, such as a polymeric carrier.

Abstract: A method for treating a patient for adult-onset dementia of the Alzheimer's type by removing a portion of the patient's cerebrospinal fluid, preferably (although not necessarily) by transporting the fluid to another portion of the patient's body. The invention also provides an apparatus for removing cerebrospinal fluid including (1) a conduit with a first opening and a second opening, the first opening of the conduit being adapted to be disposed in fluid communication with a space within a patient's arachnoid membrane, the second opening being adapted to be disposed in fluid communication with another portion of the patient's body; and (2) a flow rate control device attached to the conduit.

Abstract: Non-invasive angiography is provided through use of monochromatized synchrotron radiation in a dichromographic procedure. A small quantity of an iodinated compound is introduced into the blood stream of a patient. An X-ray picture of a blood vessel such as the coronary artery can be produced by directing synchrotron radiation from a storage ring source at first and second selected wavelengths or energy levels through the blood vessel, detecting the attenuated radiation to obtain first and second signals representative of the attenuated radiation, and logarithmically subtracting the two signals to essentially eliminate all background contrast. Due to the K-absorption edge of iodine the resulting signal will emphasize the blood vessel containing the iodine.

Abstract: A novel immunoassay is provided, as well as particular reagents, for determining the presence of a ligand. A Reagent is employed having at least two epitopes, one of the epitopes being common with the ligand, and the other epitopes being foreign to the ligand. The two epitopes are positioned in the Reagent so that antibody bound to one of the epitopes sterically inhibits the binding of antibody to the second epitope.In carrying out the assay, the sample, the Reagent, and antibodies to the two epitopes are combined. Because of the steric inhibition to the simultaneous binding of the two antibodies to the Reagent, the amount of antibody bound to the epitope of the Reagent foreign to the ligand will be related to the amount of ligand present in the assay medium. By analyzing directly or indirectly for the antibody bound to the epitope foreign to the ligand, and comparing the results to known standards, qualitative or quantitative determinations of the amount of ligand may be made.